Pfizer (PFE) Other financing activities (2009 - 2026)
Pfizer (PFE) posted quarterly Other financing activities of -$284.0 million for Q1 2026, up 20.22% year-over-year from -$236.2 million in Q1 2025, and down 560.47% quarter-over-quarter from -$43.0 million in Q4 2025.
Pfizer (PFE) Other financing activities (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Other financing activities for 18 consecutive years, with -$284.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 20.22% year-over-year to -$284.0 million; the TTM figure through Mar 2026 stood at -$386.0 million (up 69.37% YoY), while the FY2025 annual figure was -$458.0 million, up 2.35% from the prior year.
- Other financing activities retreated to -$284.0 million in Q1 2026 per PFE's latest filing, from -$43.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $154.0 million in Q3 2022 and bottomed at -$501.0 million in Q2 2022.
- Historically, Other financing activities has averaged -$199.0 million across 5 years, with a median of -$140.0 million in 2023.
- Annual changes were most pronounced in 2023 — Other financing activities plunged 190.91% — and 2025, when it surged 91.65%.
- Pfizer's Other financing activities stood at $154.0 million in 2022, then plunged by 111.69% to -$18.0 million in 2023, then plunged by 2427.78% to -$455.0 million in 2024, then surged by 90.55% to -$43.0 million in 2025, then plunged by 560.47% to -$284.0 million in 2026.
- Business Quant data shows PFE's Other financing activities at -$284.0 million in Q1 2026, -$43.0 million in Q4 2025, and -$38.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -27.00 Mn |
| Jun 28, 2026 | -27.00 Mn |
| Mar 29, 2026 | -284.00 Mn |
| Mar 29, 2026 | -284.00 Mn |
| Dec 31, 2025 | -43.00 Mn |
| Dec 31, 2025 | -43.00 Mn |
| Sep 28, 2025 | -38.00 Mn |
| Sep 28, 2025 | -38.00 Mn |
| Jun 29, 2025 | -21.00 Mn |
| Jun 29, 2025 | -21.00 Mn |
| Mar 30, 2025 | -356.00 Mn |
| Mar 30, 2025 | -356.00 Mn |
| Sep 29, 2024 | -455.00 Mn |
| Sep 29, 2024 | -455.00 Mn |
| Jun 30, 2024 | -63.00 Mn |
| Jun 30, 2024 | -63.00 Mn |
| Mar 31, 2024 | -386.00 Mn |
| Mar 31, 2024 | -386.00 Mn |
| Dec 31, 2023 | -18.00 Mn |
| Dec 31, 2023 | -18.00 Mn |